Sutro Biopharma, Inc. (STRO)
Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies and other biologics. It employs its proprietary Cell-Free Protein Synthesis platform to develop biologics with precise modification and enhanced efficiency. The company's pipeline includes bispecific antibodies, antibody-drug conjugates, and novel protein therapeutics aimed at treating various cancers and other diseases.
Company News
The FDA is tightening survival standards in cancer research, with private investments helping to fill public funding gaps. Several biotech companies are advancing innovative immunotherapies, with Oncolytics Biotech showing promising results in pancreatic cancer treatment.
Sutro Biopharma presented data from the dose-optimization portion of the REFRαME-O1 trial for luveltamab tazevibulin (luvelta) in patients with platinum resistant ovarian cancer. The data showed encouraging antitumor activity and a consistent safety profile across dose levels.
Spruce Biosciences (SPRB) delivered earnings and revenue surprises of 12.50% and 79.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Phase 1 data for its ovarian cancer candidate was a little disappointing.